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Chlorhexidine (CHX) is a broad-spectrum antiseptic that is used in many topical pharmaceutical 
formulations. Because there is no official microbiological assay reported in the literature that is used to 
quantify CHX, this paper reports the development and validation of a simple, sensitive, accurate and 
reproducible agar diffusion method for the dosage of chlorhexidine digluconate (CHX-D) in an aqueous 
solution. The assay is based on the inhibitory effect of CHX-D upon the strain of Staphylococcus aureus 
ATCC 25923, which is used as the test microorganism. The design 3x3 parallel-line model was used. The 
results were treated statistically by analysis of variance (ANOVA), and they were excellent in terms of 
linearity (r = 0.9999), presenting a significant regression between the zone diameter of growth inhibition 
and the logarithm of the concentration within the range of 0.5 to 4.5%. The results obtained were precise, 
having relative standard deviations (RSD) for intra-day and inter-day precision of 2.03% and 2.94%, 
respectively. The accuracy was 99.03%. The method proved to be very useful and appropriate for the 
microbiological dosage of CHX-D in pharmaceutical formulations; it might also be used for routine 
drug analysis during quality control in pharmaceutical industries. 
Uniterms: Agar diffusion. Antiseptic. Chlorhexidine. Microbiological assay. Quality control. Validation.
Clorexidina (CHX) é um antisséptico com amplo espectro de ação utilizada em muitos tipos de 
preparações farmacêuticas para uso tópico. Uma vez que não há na literatura ensaio microbiológico 
oficial para quantificar a clorexidina, este trabalho objetivou o desenvolvimento e validação de um 
ensaio microbiológico simples, sensível, exato e reprodutível, por difusão em ágar, para doseamento 
de digliconato de clorexidina (CHX-D) em solução aquosa. O ensaio é baseado no efeito da inibição 
de Staphylococcus aureus ATCC 25923, utilizado como microorganismo teste, pela CHX-D. Utilizou-
se o delineamento 3x3. Os resultados foram verificados estatisticamente pela análise de variância 
(ANOVA) e apresentaram excelente linearidade (r = 0,9999), demonstrando que o método segue 
o modelo linear com regressão significativa entre o diâmetro da zona de inibição e o lagaritmo da 
concentração no intervalo de 0,5 a 4,5%. Os resultados obtidos foram precisos apresentando desvio 
padrão relativo (DPR) para precisão intra-dia de 2,03% e DPR para precisão inter-dias de 2,94%. A 
exatidão foi 99,03%. O método provou ser muito útil e apropriado para doseamento microbiológico 
da CHX-D em formas farmacêuticas e pode ser empregado para análise desta substância no controle 
de qualidade em indústrias farmacêuticas.
Unitermos: Difusão em ágar. Antisséptico. Clorexidina. Ensaio microbiológico. Controle de qualidade. 
Validação.
INTRODUCTION
Antiseptics are products that are used to clean and 
disinfect traumatic wounds, burns, mucous membranes, 
hands, and surgical sites and are sometimes used to 
impregnate catheters (Fiorentino, Corrêa, Salgado, 2010).
Chlorhexidine (CHX) is an excellent cationic 
antiseptic that belongs to a class of drugs called biguanides 
and has the chemical name (1,1’-hexamethylenebis{5-
(p-chlorophenyl)biguanide)} (Buxbaum et al., 2006; 
USP, 2008; BP, 2010; EP, 2011). It exists as a variety 
of salts, including acetate, gluconate, hydrochloride 
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and digluconate, but the digluconate form (Figure 1) is 
the most soluble in water and at physiological pH (EP, 
2011; Thomas et al., 2000; Martindale, 2009). CHX is 
active against Gram-positive bacteria; less active against 
Gram-negative bacteria, fungi, and species of Proteus; 
and has activity against certain types of enveloped 
viruses, including hepatitis virus, herpes simplex, HIV, 
cytomegalovirus, influenza and respiratory syncytial virus. 
For mycobacteria, the CHX exhibits minimal activity; 
against endospores and cysts of protozoa the activity is 
nil (Fiorentino, Corrêa, Salgado, 2010; Cone et al., 2006; 
Martindale, 2009). 
There are many uses for CHX. It is most likely 
the most widely used biocide in antiseptic products, 
specifically in hand-washing and oral products; it is also 
used to impregnate catheters or other medical products, as 
a preservative in vaginal gel, as a disinfectant (Cone et al., 
2006; Galice et al., 2006) and as a surgical scrub to clean 
the site of surgery (Buxbaum et al., 2006).
Standard physicochemical methods for the 
determination of CHX are described in the European, 
British and United States Pharmacopoeias (USP, 2008; 
BP, 2010; EP, 2011). These techniques employ high 
performance liquid chromatography (HPLC) (USP, 2008; 
BP, 2010; EP, 2011) or titration with 0.1 M perchloric 
acid (BP, 2010; EP, 2011). The methods described in the 
literature to analyse degradation products of CHX and 
related substances are HPLC (USP, 2008) and colorimetric 
tests (BP, 2010; EP, 2011). 
The literature describes several methods for 
the determination of CHX in biological fluids, which 
include direct UV spectroscopy (Jensen, Christensen, 
1971), fluorometry (Vries, Ruben, Arends, 1991), HPLC 
(Gaffney, Cooke, 1984; Brougham, Cheng, Pittman, 1986; 
Lam et al., 1993; Pesonem, Holmalahti, Pohjola, 1995; 
Below, Lehan, Kramer, 2004) and liquid chromatography-
electrospray ionisation mass spectrometry (LC-ESI-MS) 
(Usui et al., 2006). For pharmaceutical products that 
contain CHX, several physicochemical methods are 
presented, such as HPLC (Gavlick, 1992; Há, Cheung, 
1996; Izumoto et al., 1997; Havlíková et al., 2007), solid-
phase extraction with UV spectrophotometry (Bonazzi 
et al., 1995), gas-liquid chromatography (Miribel et al., 
1983), and capillary electrophoresis (Abad-Villar et al., 
2006).
A standard microbiological assay has not been 
reported to determine the potency of CHX digluconate in an 
aqueous solution using an agar diffusion test. However, in 
the literature, there are a large number of reports describing 
the use of microbiological assays to assess the potency of 
many antibiotics (Marona, Schapoval, 1998; Mendez et al., 
2005; Gomes, Salgado, 2006; Salgado, Lopes, Lucchesi, 
2006; Vaugher, Breier, Schapoval, 2006; Souza et al., 2007; 
Moreno, Salgado, 2007; Salgado, Tozo, 2007; Schmidt et 
al., 2008; Lopes, Salgado, 2010; Cazedey, Salgado, 2011; 
Paim et al., 2011; Solano et al., 2011). 
Although biological assays have a high variability, 
a microbiological assay can reveal subtle changes that are 
not demonstrable by chemical methods. A bioassay is an 
environmentally friendly technique because it does not 
require solvent or produce toxic by-products. Moreover, a 
microbiological assay requires no specialised equipment, 
is low in cost, is a simple procedure and requires only a 
simple facility to obtain results. These factors make the 
use of microbiological assays a very good alternative 
methodology for a potency assessment of antimicrobial 
drugs in a quality control laboratory (Salgado, Lopes, 
Lucchesi, 2006; Vaugher, Breier, Schapoval, 2006; Souza 
et al., 2007; Schmidt et al., 2008; Lopes, Salgado, 2010; 
Paim et al., 2011). Additionally, the excipients used for 
physicochemical techniques often cause interference and 
require expensive and sophisticated equipment that is not 
available in some quality control laboratories (Schmidt 
et al., 2008).
The aim of the present study was to develop 
and validate a simple, sensitive, precise and accurate 
microbiological assay by agar diffusion using a template 
method to quantify CHX-D in aqueous solution as an 
ecological alternative to the physicochemical methods 
described in the literature.
MATERIAL AND METHODS
Chemicals
The CHX digluconate aqueous standard solution 
(purity 20.0%, batch number: 07/1306) was kindly donated 
by Rioquímica LTDA (Brazil). The CHX digluconate 
aqueous solution (Henrifarma®, Brazil) (rotulated purity 
FIGURE 1 - Chemical structure of chlorhexidine digluconate 
(CAS: 18472-51-0).
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20.0%, batch number: CS 0120705) was kindly donated 
by the Cosmetology Laboratory of Universidade Estadual 
Paulista (UNESP) (Brazil). Purified water was used in all 
experiments.
Preparation of solutions
Chlorhexidine digluclonate reference solutions
Aliquots of 250 µL, 750 µL and 2250 µL of the 
aqueous CHX digluconate reference solution were 
transferred to 10-mL volumetric flasks, which were filled 
with water to give concentrations of 0.5, 1.5 and 4.5% (S1, 
S2 and S3), respectively. These standard solutions were 
used in the bioassay. 
Preparation of the sample solutions
Aliquots of 250 µL, 750 µL and 2250 µL of a CHX 
digluconate aqueous solution were transferred to 10-mL 
volumetric flasks, which were filled with water to give 
concentrations of 0.5, 1.5 and 4.5% (T1, T2 and T3), 
respectively. These standard solutions were tested against 
S1, S2 and S3. 
Microorganism and inoculum standardisation
The cultures of S. aureus ATCC 25923 were 
cultivated on casein-soy agar (Acumedia®) at a temperature 
near freezing (2.0 to 8.0 ºC). The microorganism 
standardisation was carried out according to the 
procedures described in the Brazilian and United States 
Pharmacopoeias (USP, 2008; F. BRAS., 2010). Prior to 
use, the microorganism was grown in Brain Heart Infusion 
(BHI) broth (BD®) in a test tube that was incubated for 24 h 
at 35 ºC ± 2 ºC. Using a spectrophotometer (Beckman, 
DU® 530) with the wavelength set at 580 nm and a 10 mm 
absorption cell, the broth containing the microorganism 
was diluted to achieve a suspension turbidity of 25 ± 2% 
(transmittance) using the same sterile broth solution as 
for the blank. From this standardised suspension, 1.0 mL 
aliquots were added to each 100 mL of BHI agar (BD®) at 
47 ºC ± 1 ºC and used as the inoculum layer in the plate.
Agar diffusion bioassay
The bioassay described previously followed the 3 
x 3 parallel line assay design (three doses of the standard 
and three doses of the sample in each plate), with six plates 
for each assay, according to the Brazilian Pharmacopoeia 
(F. BRAS., 2010). The agar was composed of two separate 
layers. The BHI agar (20 mL) was poured into a 100 mm 
x 20 mm Petri dish as a base layer. After solidification of 
this layer, a 5 mL portion of the inoculated BHI agar was 
poured onto the base layer. 
In each plate, a template was placed on the surface 
of the inoculated medium. Three alternating holes were 
filled with 200 µL of the reference solution (S1, S2 and 
S3), and the other three holes were filled with the sample 
solutions (T1, T2 and T3). Six plates were used in each 
assay. The plates were incubated at 35 ± 1 ºC under aerobic 
conditions for 18 hours. The diameters (mm) of the zones 
of inhibition were carefully measured using a digital 
calliper (Mitutoyo® IP 65) (Figure 2). All experiments 
were performed in a biological safety cabinet, and the 
infected material was decontaminated before being 
discarded. 
Method validation
The method was validated by the determination of 
linearity, precision and accuracy (USP, 2008; Marona, 
Schapoval, 1998; Gomes, Salgado, 2007; Salgado, Lopes, 
Lucchesi, 2006; Moreno, Salgado, 2007; Salgado, Tozo, 
2007; Lopes, Salgado, 2010; Cazedey, Salgado, 2011; 
Paim et al., 2011; ICH, 2005; AOAC, 2005).
Linearity
To assess the validity of the assay, three doses of 
the standard and three doses of the sample were used. 
The linearity was evaluated by linear regression analysis, 
which was calculated using the least squares method.
Precision
The precision of the method was determined by 
repeatability (intra-assay) and the intermediate precision 
(inter-assay) and was expressed as the relative standard 
deviation (RSD). The repeatability was verified by 
assaying samples of CHX digluconate in aqueous solution, 
at the same concentration, within one day and under the 
same experimental conditions. The intermediate precision 
was evaluated by comparing the assay results from three 
different days.
Accuracy
Accuracy was determined by adding 3 concentrations, 
which covered the specified range. Aliquots of precisely 
500, 1000 and 1500 μL of the standard solution (20%) 
were transferred into 10 mL volumetric flasks, and diluted 
with water to give final concentrations of 1.5, 2.5 and 
3.5%, respectively. The percentage recovery of the CHX 
digluconate standard was calculated using the equation 
proposed by the AOAC (2005).
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Calculation of potency
To calculate the activity of CHX digluconate in 
aqueous solution, the Hewitt [38] equation was used. The 
assays were statistically analysed using the linear parallel 
model and regression analysis and verified using analysis 
of variance (ANOVA) (USP, 2008; Marona, Schapoval, 
1998; Salgado, Gomes, Salgado, 2006; Lopes, Lucchesi, 
2006; Moreno, Salgado, 2007; Salgado, Tozo, 2007; F. 
BRAS., 2010; Lopes, Salgado, 2010; Cazedey, Salgado, 
2011; Paim et al., 2011).
RESULTS AND DISCUSSION
The development and validation of analytical 
methods for the determination of active ingredients in 
medicines is very important for quality control and patient 
safety. When choosing an analytical method for use in 
routine quality control, the analyst must consider cost, 
complexity, required time, availability of equipment and 
reagents, purity, quantity of the sample and the generation 
of residues (ICH, 2005; Salgado, Lopes, Lucchesi, 2006; 
Moreno, Salgado, 2007).
Moreover, the development and validation 
of analytical methods to determine potency, such 
as microbiological assays, have recently received 
considerable attention, mainly from regulatory agencies, 
because of their importance in pharmaceutical analysis 
(Mendez et al., 2005; Moreno, Salgado, 2007; Salgado, 
Tozo, 2007; Lopes, Salgado, 2010; Cazedey, Salgado, 
2011). Microbiological assays have the potential to prevent 
the possible loss of activity, while physicochemical 
methods do not prevent the loss of the antimicrobial 
potency (USP, 2008).
For this reason, a microbiological assay was 
proposed as a suitable method for the determination of 
CHX digluconate in aqueous solution.
The experimental conditions were tested and 
adjusted to accurately determine the performance of the 
assay. Some parameters were tested previously to establish 
the described conditions and shown in Table I. The strain 
of Staphylococcus aureus that was used, ATCC 25923, 
appears to be an appropriate test microorganism because 
of its susceptibility to CHX-D and its capacity to form 
sharply defined zones of growth inhibition, allowing for 
precise measurements.
The potency of an antibiotic may be demonstrated 
under suitable conditions by comparing the inhibition 
of growth of a microorganism caused by known 
concentrations of the antibiotic and a reference standard 
(USP, 2008; F. BRAS., 2010; EP, 2011). 
Method validation
In this experimental work, a 3 x 3 design was 
used, using three concentrations of both a standard and 
sample solution, according to the procedure described 
in the Brazilian Pharmacopoeia (F. BRAS., 2010). The 
calculation assumes a direct relationship between the 
observed diameter of the zone of inhibition and the 
logarithm of the applied dose. The growth inhibition zones 
of aqueous solutions of CHX digluconate and the reference 
substance are shown in Figure 2. 
Table II gives the results, represented as the 
diameters of the zones of inhibition, for CHX digluconate 
in aqueous solution.
TABLE I - Tested conditions to establish the parameters for 
microbiological assay of CHX digluconate
Parameter Condition
Standard curve (μg/mL) 1.5, 3.0, 6.0%; 0.25, 1.0, 4.0% 
and 0.5, 1.5, 4.5%
Diluents Buffer solution pH 6.0 and 
pH 8.0
Purified water
Inoculum (%) 0.5 and 1.0
Microorganism Bacillus subtilis ATCC 9372
Staphylococcus aureus ATCC 
25923
Culture media Mueller Hinton agar
Brain Heart Infusion (BHI) 
agar
FIGURE 2 - An agar diffusion assay using a strain of S. aureus 
ATCC 25923 as the test microorganism. The chlorhexidine 
digluconate reference solutions are at concentrations of 0.5 (S1), 
1.5 (S2) and 4.5% (S3) and the chlorhexidine digluconate samples 
are at concentrations of 0.5 (T1), 1.5 (T2) and 4.5% (T3).
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TABLE IV - Accuracy of the microbiological assay of CHX digluconate
Run
Amount of standard (%)
Added (%) Recovered (%) Recovery (%)a RSD (%)
R1 5.00 4.93 98.6
R2 10.00 9.80 98.0 1.32
R3 15.00 15.07 100.5
aMean of 3 assays
TABLE III - Analysis of variance of determination of CHX 
digluconate by bioassay
Parameters F calc F tab
Linear regression 154264.9* 4.24
Linearity deviation 3.159 3.38
Parallelism 0.182 4.24
* p < 0.05).
TABLE II - Diameters of the zones of inhibition for CHX digluconate in aqueous solution and the reference solution, obtained using 
a standard curve
Concentration (%) Range of zone size, mm Means diameters of growth inhibition zonesa, mm RSD%
0.5 19.27 – 19.32 19.30 0.9
1.5 20.79 – 20.84 20.81 1.0
4.5 22.33 – 22.39 22.37 1.1
aMean of 3 assays with 6 plates in each.
The calibration curve for CHX digluconate in 
aqueous solution was constructed by plotting the zone 
diameter (mm) versus the log of the concentration (%) and 
showed good linearity in the 0.5 to 4.5% range. 
The representative linear equation for CHX 
digluconate was y = 1.3972 Ln(x) + 20.26, where x is 
the log dose and y is the zone diameter. The coefficient 
of regression was 0.9999, which is highly significant for 
the method. According to the Brazilian and the United 
States Pharmacopoeias (USP, 2008; F. BRAS., 2010), if a 
parallel-line model is chosen, the two log dose-response 
lines of the preparations to be examined, as well as that of 
the reference preparation, must be parallel, and they must 
be linear over the range of doses used in the calculation. 
These conditions must be verified by validity tests for 
a given probability, usually p = 0.05. The assays were 
validated by analysis of variance (ANOVA), as described 
in those official codes. There were no deviations from 
parallelism or linearity in the obtained results (p < 0.05) 
(Table III). 
The method precision in terms of repeatability 
(intra-assay) shows a mean R.S.D. of 2.03%, indicating 
good intra-day precision for the method. The intermediate 
precision shows a mean R.S.D. of 2.94%.
The mean accuracy was 99.03%, and the R.S.D. 
was 1.32% (Table IV), which confirms the ability of the 
method to accurately determine the concentration of 
CHX digluconate in aqueous solution and shows that the 
results obtained from the bioassay were close to the true 
concentrations of the samples.
Calculation of potency
The CHX digluconate activity ranged from 92.52 
to 92.61%, with an R.S.D. value of 0.1%. This value is 
acceptable because the American Pharmacopoeia (USP, 
2008) allows for variations of up to 10% for mouth rinse. 
Moreover, CHX digluconate is a non-sterile product that 
is indicated for external use only, which allows a 10% 
variation (USP, 2008; EP, 2011). The low R.S.D. values 
that were obtained confirm that the proposed method can 
generate reproducible results with little variation between 
independent assays.
The quantification of ingredients in antiseptics 
using chemical methods, such as HPLC and UV 
spectrophotometry, although precise, cannot provide a true 
indication of biological activity. Therefore, bioassays play 
an essential role in the manufacturing and quality control 
of antibiotics. This study confirms the validity of using 
bioassays for the quality control of antiseptic medicines 
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this for antiseptic medicines, and this technique still 
demands considerable skill and expertise to ensure success 
(Vaugher, Breier, Schapoval, 2006; Lopes, Salgado, 2010; 
Cazedey, Salgado, 2011; Paim et al., 2011). Although 
biological assays might have a high variability, the analysis 
of the results demonstrates that the proposed method might 
be very useful for determination of the potency of CHX 
digluconate in aqueous solution.
The results obtained in this study were very satisfactory, 
and the validation demonstrated that microbiological assays 
are a good alternative methodology for the pharmaceutical 
analysis of CHX digluconate in aqueous solution. It is a 
useful analytical tool in conjunction with or substitution for 
a physicochemical method.
CONCLUSION
The results indicated that the microbiological assay 
demonstrated excellent linearity, precision and accuracy 
at concentrations ranging from 0.5 to 4.5%. Therefore, it 
is an acceptable alternative method for the routine quality 
control of CHX digluconate in aqueous solution. The 
method uses simple reagents, requires minimal sample 
preparation, produces no toxic residues and there is no 
sophisticated equipment required, supporting its use in 
routine analysis.
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